In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Epidemiology and long-term outcome in outpatients with chronic heart failure in north-western europe

Session Poster Session 1

Speaker Hanna Froehlich

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : H Froehlich (Heidelberg,DE), N Rosenfeld (Heidelberg,DE), T Taeger (Heidelberg,DE), K Goode (Cottingham,GB), S Kazmi (Cottingham,GB), T Hole (Trondheim,NO), HA Katus (Heidelberg,DE), D Atar (Oslo,NO), JGF Cleland (London,GB), S Agewall (Oslo,NO), AL Clark (Cottingham,GB), L Frankenstein (Heidelberg,DE), M Grundtvig (Lillehammer,NO)

Authors:
H Froehlich1 , N Rosenfeld1 , T Taeger1 , K Goode2 , S Kazmi2 , T Hole3 , HA Katus1 , D Atar4 , JGF Cleland5 , S Agewall4 , AL Clark2 , L Frankenstein1 , M Grundtvig6 , 1University Hospital of Heidelberg - Heidelberg - Germany , 2Castle Hill Hospital - Cottingham - United Kingdom of Great Britain & Northern Ireland , 3Norwegian University of Science and Technology - Trondheim - Norway , 4Oslo University Hospital - Oslo - Norway , 5Imperial College London - London - United Kingdom of Great Britain & Northern Ireland , 6Innlandet Hospital - Lillehammer - Norway ,

Citation:

Objective: To describe the epidemiology, long-term outcomes and temporal trends in mortality in ambulatory patients with chronic heart failure (HF) with reduced (HFrEF), mid-range (HFmrEF) or preserved ejection fraction (HFpEF) from three European countries.

Methods: We identified 10,312 patients from three European HF registries. Patients were classified according to baseline left ventricular ejection fraction (LVEF) and time of enrolment (period 1: 1995-2005 vs. period 2: 2006-2015). Predictors of mortality were analysed by use of univariable and multivariable Cox regression analyses.

Results: Among 10,312 patients with stable HF, 7,080 (68.7%), 2,086 (20.2%), and 1,146 (11.1%) were classified as having HFrEF, HFmrEF, or HFpEF, respectively. A total of 4,617 (44.8%) patients was included in period 1, and 5,695 (55.2%) patients were included in period 2. Baseline characteristics significantly differed with respect to type of HF and time of enrolment. During a median follow-up of 66 (33-105) months, 5,297 patients (51.4%) died. In multivariable analyses, survival was independent of LVEF category (p>0.05), while mortality was lower in period 2 as compared to period 1 (HR 0.81, 95% CI 0.72-0.91, p<0.001). Significant predictors of all-cause mortality regardless of HF category were increasing age, NYHA functional class, NT-proBNP, and use of loop diuretics.

Conclusion: Ambulatory HF patients stratified by LVEF represent different phenotypes. However, after adjusting for a wide range of covariates, long-term survival is independent of LVEF category. Outcome significantly improved during the last two decades irrespective from type of HF.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are